Ionix Pharmaceuticals

Pharmaceutical company announces strategic alliance with Reckitt Benckiser

Published in Physician Law Weekly, March 23rd, 2005

Ionix Pharmaceuticals has formed a multi-product strategic alliance with Reckitt Benckiser Healthcare, a subsidiary of the global health and household products company.

The alliance provides Ionix with development and commercialization capabilities for its lead product candidate, IX-1003 for the treatment of post-operative pain.

In addition, Ionix and Reckitt Benckiser intend to collaborate on the development and commercialization of two new product candidates, IX-1004 for the treatment of chronic pain and IX-1005 for the treatment of opiate addiction.

As part of the alliance, Ionix will manage a phase II clinical trial of IX-1003...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2005-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry